BioWorld

Aug. 3, 2010

Novel MicroRNA Controls Angiogenic Switch in Model

Eli Lilly CEO Provides Hints About Firm's Global Direction

Other News To Note

Stock Movers

Trius Decreases Size of IPO Deal from $78M to $49M

After delaying its initial public offering earlier this year, Trius Therapeutics Inc. said Monday that it now plans to decrease the size of its proposed IPO deal. (BioWorld Today) Read More

Waiting for Payday: Symphony Agrees to Lexicon JV Buyout

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...